무균 주사제 수탁제조 시장 규모, 점유율 및 동향 분석 보고서 : 분자별, 제품별, 서비스별, 치료 영역별, 투여 경로별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Sterile Injectable Contract Manufacturing Market Summary

The global sterile injectable contract manufacturing market size was estimated at USD 24.5 billion in 2025 and is projected to reach USD 57.2 billion by 2033, growing at a CAGR of 11.3% from 2026 to 2033. The growth of the market is due to the increasing demand for biologics and biosimilars, along with the outsourcing trend among pharmaceutical companies seeking to reduce costs and enhance efficiency.

Moreover, the rising prevalence of chronic illnesses, coupled with the quicker approval timelines for sterile injectables compared to other drug types, is further driving the demand for injectable formulations. The growing trend of outsourcing in the pharmaceutical industry is driving market growth. Several companies, particularly small to mid-sized firms, are increasingly seeking contract manufacturing organizations (CMOs) to reduce operational costs, enhance efficiency, and focus on their core competencies. By outsourcing sterile injectable production, these companies can leverage the expertise and advanced technologies of specialized manufacturers, thereby reducing time-to-market for new products.

In addition, growing investments in pharmaceutical R&D activities are also driving the demand in the market. Companies are prioritizing innovation to develop new therapies, particularly in the sterile injectable segment. Thus, increased investment has accelerated the pipeline of injectable products, further meeting the needs of patients with chronic illnesses. Therefore, as R&D efforts rise, demand for sterile injectables is projected to grow.

Technological advancements in sterile manufacturing processes have enhanced production capabilities and efficiency. Innovations such as single-use systems, automation, and advanced containment technologies are making it easier to produce high-quality sterile injectables while minimizing contamination risks. These advancements have not only enhanced the safety and reliability of the manufacturing process but also allowed for greater customization and quicker turnaround times for clients. As companies increasingly seek to differentiate their products and optimize manufacturing operations, the integration of cutting-edge technologies into contract manufacturing services will remain a key driver of the market.

Global Sterile Injectable Contract Manufacturing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global sterile injectable contract manufacturing market report based on molecule, product, service, therapeutic area, route of administration, end use and region:

• Molecule Outlook (Revenue, USD Million, 2021 - 2033)
• Small Molecule
• Large Molecule
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• API
• Finished Drug Product
  • Prefilled Syringes
  • Vials and Ampoules
  • Specialty Injectables
  • Others
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Clinical Trial Manufacturing
• Commercial Manufacturing
• Aseptic Fill-Finish Services
• Packaging & Labelling
• Others
• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Cardiovascular Diseases
• Central Nervous System Diseases
• Infectious Disorders
• Musculoskeletal Diseases
• Hormonal Diseases
• Others
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Subcutaneous (SC)
• Intravenous (IV)
• Intramuscular (IM)
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical Companies
• Biopharmaceutical Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Molecule
  • 1.2.2. Product
  • 1.2.3. Service
  • 1.2.4. Therapeutic Area
  • 1.2.5. Route of Administration
  • 1.2.6. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Bottom-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Sterile Injectable Contract Manufacturing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Pipeline and Approvals of Injectables
    • 3.2.1.2. Growing Demand for Biologics and Biosimilars Significantly Supported Market Growth
    • 3.2.1.3. Rise in Investment Across Research & Development Activities for the Development of Novel Therapeutics
    • 3.2.1.4. Increasing Demand for Cell & Gene Therapies
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Low Barriers to Market Penetration Have Resulted in Pricing Pressure
    • 3.2.2.2. Challenges Related to Quality Control
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Value Chain Analysis
  • 3.6.1. Supply Trends
  • 3.6.2. Demand Trends
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Force Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Sterile Injectable Contract Manufacturing Market: Molecule Estimates & Trend Analysis

• 4.1. Sterile Injectable Contract Manufacturing Market, By Molecule: Segment Dashboard
• 4.2. Sterile Injectable Contract Manufacturing Market, By Molecule: Movement Analysis
• 4.3. Sterile Injectable Contract Manufacturing Market Estimates & Forecasts, By Molecule, 2021 - 2033 (USD Million)
• 4.4. Small Molecule
  • 4.4.1. Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Large Molecule
  • 4.5.1. Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Sterile Injectable Contract Manufacturing Market: Product Estimates & Trend Analysis

• 5.1. Sterile Injectable Contract Manufacturing Market, By Product: Segment Dashboard
• 5.2. Sterile Injectable Contract Manufacturing Market, By Product: Movement Analysis
• 5.3. Sterile Injectable Contract Manufacturing Market Estimates & Forecasts, By Product, 2021 - 2033 (USD Million)
• 5.4. API
  • 5.4.1. API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Finished Drug Product
  • 5.5.1. Finished Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Pre-filled Syringes
    • 5.5.2.1. Pre-filled Syringes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.3. Vials and Ampoules
    • 5.5.3.1. Vials and Ampoules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.4. Specialty Injectables
    • 5.5.4.1. Specialty Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.5. Others
    • 5.5.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Sterile Injectable Contract Manufacturing Market: Service Estimates & Trend Analysis

• 6.1. Sterile Injectable Contract Manufacturing Market, By Service: Segment Dashboard
• 6.2. Sterile Injectable Contract Manufacturing Market, By Service: Movement Analysis
• 6.3. Sterile Injectable Contract Manufacturing Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
• 6.4. Clinical Trial Manufacturing
  • 6.4.1. Clinical Trial Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Commercial Manufacturing
  • 6.5.1. Commercial Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Aseptic Fill-Finish Services
  • 6.6.1. Aseptic Fill-Finish Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Packaging & Labeling
  • 6.7.1. Packaging & Labeling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Sterile Injectable Contract Manufacturing Market: Therapeutic Area Estimates & Trend Analysis

• 7.1. Sterile Injectable Contract Manufacturing Market, By Therapeutic Area: Segment Dashboard
• 7.2. Sterile Injectable Contract Manufacturing Market, By Therapeutic Area: Movement Analysis
• 7.3. Sterile Injectable Contract Manufacturing Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033 (USD Million)
• 7.4. Oncology
  • 7.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Cardiovascular Diseases
  • 7.5.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Central Nervous System Diseases
  • 7.6.1. Central Nervous System Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Infectious Disorders
  • 7.7.1. Infectious Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Musculoskeletal Diseases
  • 7.8.1. Musculoskeletal Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.9. Hormonal Diseases
  • 7.9.1. Hormonal Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.10. Others
  • 7.10.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Sterile Injectable Contract Manufacturing Market: Route of Administration Estimates & Trend Analysis

• 8.1. Sterile Injectable Contract Manufacturing Market, By Route of Administration: Segment Dashboard
• 8.2. Sterile Injectable Contract Manufacturing Market, By Route of Administration: Movement Analysis
• 8.3. Sterile Injectable Contract Manufacturing Market Estimates & Forecasts, By Route of Administration, 2021 - 2033 (USD Million)
• 8.4. Subcutaneous (SC)
  • 8.4.1. Subcutaneous Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Intravenous (IV)
  • 8.5.1. Intravenous (IV) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Intramuscular (IM)
  • 8.6.1. Intramuscular (IM) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Others
  • 8.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Sterile Injectable Contract Manufacturing Market: End Use Estimates & Trend Analysis

• 9.1. Sterile Injectable Contract Manufacturing Market, By End Use: Segment Dashboard
• 9.2. Sterile Injectable Contract Manufacturing Market, By End Use: Movement Analysis
• 9.3. Sterile Injectable Contract Manufacturing Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033 (USD Million)
• 9.4. Pharmaceutical Companies
  • 9.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.5. Biopharmaceutical Companies
  • 9.5.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.6. Others
  • 9.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Sterile Injectable Contract Manufacturing Market: Regional Estimates & Trend Analysis

• 10.1. Regional Market Dashboard
• 10.2. Regional Market Share Analysis, 2025 & 2033
• 10.3. North America
  • 10.3.1. North America Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.3.2. U.S
    • 10.3.2.1. Key Country Dynamics
    • 10.3.2.2. Competitive Scenario
    • 10.3.2.3. Regulatory Framework
    • 10.3.2.4. U.S. Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.3.3. Canada
    • 10.3.3.1. Key Country Dynamics
    • 10.3.3.2. Competitive Scenario
    • 10.3.3.3. Regulatory Framework
    • 10.3.3.4. Canada Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.3.4. Mexico
    • 10.3.4.1. Key Country Dynamics
    • 10.3.4.2. Competitive Scenario
    • 10.3.4.3. Regulatory Framework
    • 10.3.4.4. Mexico Market Estimates and Forecasts, 2021-2033 (USD Million)
• 10.4. Europe
  • 10.4.1. Europe Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.4.2. UK
    • 10.4.2.1. Key Country Dynamics
    • 10.4.2.2. Competitive Scenario
    • 10.4.2.3. Regulatory Framework
    • 10.4.2.4. UK Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.4.3. Germany
    • 10.4.3.1. Key Country Dynamics
    • 10.4.3.2. Competitive Scenario
    • 10.4.3.3. Regulatory Framework
    • 10.4.3.4. Germany Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.4.4. France
    • 10.4.4.1. Key Country Dynamics
    • 10.4.4.2. Competitive Scenario
    • 10.4.4.3. Regulatory Framework
    • 10.4.4.4. France Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.4.5. Italy
    • 10.4.5.1. Key Country Dynamics
    • 10.4.5.2. Competitive Scenario
    • 10.4.5.3. Regulatory Framework
    • 10.4.5.4. Italy Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.4.6. Spain
    • 10.4.6.1. Key Country Dynamics
    • 10.4.6.2. Competitive Scenario
    • 10.4.6.3. Regulatory Framework
    • 10.4.6.4. Spain Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.4.7. Denmark
    • 10.4.7.1. Key Country Dynamics
    • 10.4.7.2. Competitive Scenario
    • 10.4.7.3. Regulatory Framework
    • 10.4.7.4. Denmark Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.4.8. Sweden
    • 10.4.8.1. Key Country Dynamics
    • 10.4.8.2. Competitive Scenario
    • 10.4.8.3. Regulatory Framework
    • 10.4.8.4. Sweden Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.4.9. Norway
    • 10.4.9.1. Key Country Dynamics
    • 10.4.9.2. Competitive Scenario
    • 10.4.9.3. Regulatory Framework
    • 10.4.9.4. Norway Market Estimates and Forecasts, 2021-2033 (USD Million)
• 10.5. Asia Pacific
  • 10.5.1. Asia Pacific Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.5.2. Japan
    • 10.5.2.1. Key Country Dynamics
    • 10.5.2.2. Competitive Scenario
    • 10.5.2.3. Regulatory Framework
    • 10.5.2.4. Japan Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.5.3. China
    • 10.5.3.1. Key Country Dynamics
    • 10.5.3.2. Competitive Scenario
    • 10.5.3.3. Regulatory Framework
    • 10.5.3.4. China Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.5.4. India
    • 10.5.4.1. Key Country Dynamics
    • 10.5.4.2. Competitive Scenario
    • 10.5.4.3. Regulatory Framework
    • 10.5.4.4. India Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.5.5. Thailand
    • 10.5.5.1. Key Country Dynamics
    • 10.5.5.2. Competitive Scenario
    • 10.5.5.3. Regulatory Framework
    • 10.5.5.4. Thailand Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.5.6. South Korea
    • 10.5.6.1. Key Country Dynamics
    • 10.5.6.2. Competitive Scenario
    • 10.5.6.3. Regulatory Framework
    • 10.5.6.4. South Korea Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.5.7. Australia
    • 10.5.7.1. Key Country Dynamics
    • 10.5.7.2. Competitive Scenario
    • 10.5.7.3. Regulatory Framework
    • 10.5.7.4. Australia Market Estimates and Forecasts, 2021-2033 (USD Million)
• 10.6. Latin America
  • 10.6.1. Latin America Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.6.2. Brazil
    • 10.6.2.1. Key Country Dynamics
    • 10.6.2.2. Competitive Scenario
    • 10.6.2.3. Regulatory Framework
    • 10.6.2.4. Brazil Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.6.3. Argentina
    • 10.6.3.1. Key Country Dynamics
    • 10.6.3.2. Competitive Scenario
    • 10.6.3.3. Regulatory Framework
    • 10.6.3.4. Argentina Market Estimates and Forecasts, 2021-2033 (USD Million)
• 10.7. MEA
  • 10.7.1. MEA Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.7.2. South Africa
    • 10.7.2.1. Key Country Dynamics
    • 10.7.2.2. Competitive Scenario
    • 10.7.2.3. Regulatory Framework
    • 10.7.2.4. South Africa Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.7.3. Saudi Arabia
    • 10.7.3.1. Key Country Dynamics
    • 10.7.3.2. Competitive Scenario
    • 10.7.3.3. Regulatory Framework
    • 10.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.7.4. UAE
    • 10.7.4.1. Key Country Dynamics
    • 10.7.4.2. Competitive Scenario
    • 10.7.4.3. Regulatory Framework
    • 10.7.4.4. UAE Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.7.5. Kuwait
    • 10.7.5.1. Key Country Dynamics
    • 10.7.5.2. Competitive Scenario
    • 10.7.5.3. Regulatory Framework
    • 10.7.5.4. Kuwait Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.7.6. Oman
    • 10.7.6.1. Key Country Dynamics
    • 10.7.6.2. Competitive Scenario
    • 10.7.6.3. Regulatory Framework
    • 10.7.6.4. Oman Market Estimates and Forecasts, 2021-2033 (USD Million)
  • 10.7.7. Qatar
    • 10.7.7.1. Key Country Dynamics
    • 10.7.7.2. Competitive Scenario
    • 10.7.7.3. Regulatory Framework
    • 10.7.7.4. Qatar Market Estimates and Forecasts, 2021-2033 (USD Million)

Chapter 11. Competitive Landscape

• 11.1. Key Participant Categorization
  • 11.1.1. Market Leaders
  • 11.1.2. Emerging Players
• 11.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
• 11.3. Company Profiles
  • 11.3.1. Baxter
    • 11.3.1.1. Company Overview
    • 11.3.1.2. Financial Performance
    • 11.3.1.3. Service Benchmarking
    • 11.3.1.4. Strategic Initiatives
  • 11.3.2. Catalent, Inc.
    • 11.3.2.1. Company Overview
    • 11.3.2.2. Financial Performance
    • 11.3.2.3. Service Benchmarking
    • 11.3.2.4. Strategic Initiatives
  • 11.3.3. Vetter Pharma
    • 11.3.3.1. Company Overview
    • 11.3.3.2. Financial Performance
    • 11.3.3.3. Service Benchmarking
    • 11.3.3.4. Strategic Initiatives
  • 11.3.4. Recipharm AB
    • 11.3.4.1. Company Overview
    • 11.3.4.2. Financial Performance
    • 11.3.4.3. Service Benchmarking
    • 11.3.4.4. Strategic Initiatives
  • 11.3.5. Aenova Group
    • 11.3.5.1. Company Overview
    • 11.3.5.2. Financial Performance
    • 11.3.5.3. Service Benchmarking
    • 11.3.5.4. Strategic Initiatives
  • 11.3.6. Fresenius Kabi AG
    • 11.3.6.1. Company Overview
    • 11.3.6.2. Financial Performance
    • 11.3.6.3. Service Benchmarking
    • 11.3.6.4. Strategic Initiatives
  • 11.3.7. Unither Pharmaceuticals
    • 11.3.7.1. Company Overview
    • 11.3.7.2. Financial Performance
    • 11.3.7.3. Service Benchmarking
    • 11.3.7.4. Strategic Initiatives
  • 11.3.8. FAMAR Health Care Services
    • 11.3.8.1. Company Overview
    • 11.3.8.2. Financial Performance
    • 11.3.8.3. Service Benchmarking
    • 11.3.8.4. Strategic Initiatives
  • 11.3.9. Cipla Inc.
    • 11.3.9.1. Company Overview
    • 11.3.9.2. Financial Performance
    • 11.3.9.3. Service Benchmarking
    • 11.3.9.4. Strategic Initiatives
  • 11.3.10. NextPharma Technologies
    • 11.3.10.1. Company Overview
    • 11.3.10.2. Financial Performance
    • 11.3.10.3. Service Benchmarking
    • 11.3.10.4. Strategic Initiatives